300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape

Posted on
by

300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape

The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell Therapy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chimeric Antigen Receptor T-Cell Therapy NDA approvals (if any), and product development activities comprising the technology, Chimeric Antigen Receptor T-Cell Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

 

  • DelveInsight’s Chimeric Antigen Receptor T-Cell Therapypipeline report depicts a robust space with 300+ active players working to develop 300+ pipeline therapies for Chimeric Antigen Receptor T-Cell Therapy treatment.

 

  • The leading Chimeric Antigen Receptor T-Cell Therapy Companies includes Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai UniChimeric Antigen Receptor T-Cell Therapyherapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, and others.

 

  • Promising Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies includes Breyanzi, Kymriah, CT103A, CEA Chimeric Antigen Receptor T-Cell Therapy, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted Chimeric Antigen Receptor T-Cell Therapy cells, TT11, CD19+CD22 Chimeric Antigen Receptor T-Cell Therapy cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 Chimeric Antigen Receptor T-Cell Therapy, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, Chimeric Antigen Receptor T-Cell Therapy CD30, PCAR-19B, BCMA Chimeric Antigen Receptor T-Cell Therapy cells, CD123 Chimeric Antigen Receptor T-Cell Therapy cells, CD19 Chimeric Antigen Receptor T-Cell Therapy cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous Chimeric Antigen Receptor T-Cell Therapy CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, Chimeric Antigen Receptor T-Cell Therapy cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 Chimeric Antigen Receptor T-Cell Therapy cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T-Cell Therapy Cells, Humanized CD19 Chimeric Antigen Receptor T-Cell Therapy cells, Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T-Cell Therapy Cell Immunotherapy, Mesothelin Chimeric Antigen Receptor T-Cell Therapy cell therapy, and others.

 

  • The Chimeric Antigen Receptor T-Cell Therapy Companies and academics are working to assess challenges and seek opportunities that could influence Chimeric Antigen Receptor T-Cell Therapy R&D. The Chimeric Antigen Receptor T-Cell Therapy pipeline therapies under development are focused on novel approaches to treat/improve Chimeric Antigen Receptor T-Cell Therapy.

 

To explore more information on the latest breakthroughs in the Chimeric Antigen Receptor T-Cell Therapy Pipeline treatment landscape of the report, click here @ Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook

 

Chimeric Antigen Receptor T-Cell Therapy Overview

Chimeric antigen receptor (CAR) T-cell therapy is a kind of cancer treatment that uses specially aletered T-cells- a part of the immune system. It seeks to sharpen and strengthen the immune system’s power to fight the cancer cells. the A sample of a patient’s T cells are collected from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface. When these CAR T cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patient’s tumor cells and kill them.

 

Recent Developments Activities in the Chimeric Antigen Receptor T-Cell Therapy Treatment Landscape

 

  • In May 2022, Novartis announced the US Food and Drug Administration (FDA) had granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. Kymriah is now FDA-approved in three indications and remains the only Chimeric Antigen Receptor T-Cell Therapy cell therapy approved in both adult and pediatric settings.
  • In April 2022, the FDA approved axicabtagene ciloleucel (brand name Yescarta) for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for treating patients with primary central nervous system lymphoma.
  • In March 2022, JW Therapeutics announced that it had received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a pivotal clinical trial of its anti-CD19 autologous chimeric antigen receptor T (Chimeric Antigen Receptor T-Cell Therapy) cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) in the treatment of second-line large B-Cell lymphoma.
  • In February 2022, Fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy (CT103A) received orphan drug designation (ODD) from the FDA for the treatment of relapsed and/or refractory multiple myeloma (R/R MM), according to a press release by IASO Biotherapeutics.
  • In June 2021, based on ZUMA-3 study data, the US FDA accepted the supplemental Biologics License Application (sBLA) and granted Priority Review designation for Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.
  • In April 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that they had submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel for the treatment of patients with relapsed and refractory multiple myeloma.
  • In March 2021, the FDA approved Abecma (idecabtagene vicleucel), a cell-based CAR T – Cell Therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after at least four prior lines (different types) of therapy. Abecma is the first cell-based CAR T – Cell Therapy approved by the FDA for treating multiple myeloma.

 

For further information, refer to the detailed Chimeric Antigen Receptor T-Cell Therapy Unmet Needs, Chimeric Antigen Receptor T-Cell Therapy Market Drivers, and Chimeric Antigen Receptor T-Cell Therapy Market Barriers, click here for @ Chimeric Antigen Receptor T-Cell Therapy Ongoing Clinical Trial Analysis

 

Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs Profile

 

JWCAR029: JW Therapeutics

 

JWCAR029 is a Chimeric Antigen Receptor T-Cell Therapy cell product targeting CD19, which is intended to treat late-stage lymphoma and leukemia (Second-line therapy or greater). Initially, JWCAR029 is being studied for the treatment of B-cell malignancies focusing on relapsed and refractory DCBCL. In June 2020, the National Medical Products Administration (“NMPA”) accepted for review its NDA relating to relma-cel as a third-line treatment for DLBCL. The drug is in preregistration phase for the treatment of diffuse large B-cell lymphoma.

 

CEA CAR T: Sorrento Therapeutics 

Sorrento Therapeutics through its wholly-owned subsidiary TNK Therapeutics is developing CEA CAR T. It is a CAR T-cells targeting carcinoembryonic antigen (CEA). The drug is being studied in phase II/III stage of development for the treatment of Malignant Tumor of Pancreas Metastatic to Liver.

 

Descartes-11: Cartesian Therapeutics

Descartes-011 are autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor. Descartes-11 is currently in phase II clinical trials to treat patients with multiple myeloma in an outpatient setting.

 

CNCT19: CASI Pharmaceuticals/Juventas Cell Therapy

CNCT19 is being developed by CASI Pharmaceuticals in collaboration with Juventas Cell Therapy. CNCT19 is currently in Phase II for Non-Hodgkin’s Lymphoma, Relapsed or Refractory Acute Lymphoblastic Leukemia and Phase I/II for Large B-cell Lymphoma and Phase I for Relapsed or Refractory Hematological Malignancies.

 

CTL119: Novartis 

CTL119 (CD19 CAR) is a humanized CD19 CAR under development by Novartis in collaboration with the University of Pennsylvania and currently is in Phase II stage for the treatment of Acute Lymphoid Leukemia. CTL119 is produced with a patient’s T-cells, some of which are removed and then reprogrammed in Penn’s Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to demonstrate the T cells to target and kill tumor cells. The engineered cells contain an antibody-like protein known as a CAR, which is designed to bind to CD19 protein on the surface of cancerous B cells. The modified “hunter” cells are then infused back into the patient’s body, where they multiply and are believed to attack the cancer cells.

 

KTE-X19: Gilead Sciences 

KTE-X19 is an investigational, autologous, CD19 CAR T-cell therapy. The drug uses the XLP manufacturing process that includes T-cell selection and lymphocyte enrichment. KTE-X19 is currently in clinical evaluation for the treatment of Precursor B-cell lymphoblastic leukemia/lymphoma, Non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL).

 

CART-19/22: Shanghai UniChimeric Antigen Receptor T-Cell Therapyherapy Bio-medicine Technology

Shanghai UniChimeric Antigen Receptor T-Cell Therapyherapy Bio-medicine Technology is developing CART-19/22 for the treatment of B-Cell Leukemia and currently, it is in Phase II clinical trial. The potential therapy is CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART).

 

Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapeutics Assessment

There are approx. 300+ key companies which are developing the therapies for Chimeric Antigen Receptor T-Cell Therapy. The companies which have their Chimeric Antigen Receptor T-Cell Therapy drug candidates in the most advanced stage, i.e. pregistration include, JW therapeutics.

 

Request a sample and discover the recent advances in Chimeric Antigen Receptor T-Cell Therapy Ongoing Clinical Trial Analysis and Medications, click here @ Chimeric Antigen Receptor T-Cell Therapy Treatment Landscape

 

Scope of the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

 

  • Coverage- Global

 

  • Chimeric Antigen Receptor T-Cell Therapy Companies- Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai UniChimeric Antigen Receptor T-Cell Therapyherapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, and others.

 

  • Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies- Breyanzi, Kymriah, CT103A, CEA Chimeric Antigen Receptor T-Cell Therapy, Descartes-11, CNCT19, CTL119, P-BCMA-101, CD19/CD20/CD22/CD30 CAR T-cell therapy, CD19-targeted CAR T-cells, EPCAM-targeted Chimeric Antigen Receptor T-Cell Therapy cells, TT11, CD19+CD22 Chimeric Antigen Receptor T-Cell Therapy cell sequential therapy, CART-19/22, MB-CART2019.1, JCAR017, AUTO4, AUTO3, IM19 Chimeric Antigen Receptor T-Cell Therapy, CSG-CD19, CT053, Descartes-08, Orvacabtagene autoleucel, Chimeric Antigen Receptor T-Cell Therapy CD30, PCAR-19B, BCMA Chimeric Antigen Receptor T-Cell Therapy cells, CD123 Chimeric Antigen Receptor T-Cell Therapy cells, CD19 Chimeric Antigen Receptor T-Cell Therapy cells, ET140202, CIK-CAR.CD19, BG-T19, Autologous CD19-targeting CAR T cells (Senl-001), MB-102, Autologous Chimeric Antigen Receptor T-Cell Therapy CD44v6 cell therapy, AU101, ATA2271, AU105, AUTO1, BPX-601, Anti-CD22 CAR, Chimeric Antigen Receptor T-Cell Therapy cells targeting CD19 and CD22, huMNC2-CAR44 CAR T-cells, CD19-CART, ALLO-501A, AUTO1/22, ET 1402L1-CART, BPX-603, CAR-CD44v6, MB-106 (CD20 CAR), Anti-MUC1 Chimeric Antigen Receptor T-Cell Therapy cells, PCAR-019, PBCAR0191, PBCAR20A, PBCAR269A, BCMA CAR T-cells, CAR19 CAR T cells, MG7-CART Cells, GPC3 – CART Cells, Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T-Cell Therapy Cells, Humanized CD19 Chimeric Antigen Receptor T-Cell Therapy cells, Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T-Cell Therapy Cell Immunotherapy, Mesothelin Chimeric Antigen Receptor T-Cell Therapy cell therapy, and others.

 

  • Chimeric Antigen Receptor T-Cell Therapy Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Chimeric Antigen Receptor T-Cell Therapy Market Drivers and Chimeric Antigen Receptor T-Cell Therapy Market Barriers, click here @ Chimeric Antigen Receptor T-Cell Therapy Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction 
  2. Executive Summary
  3. Chimeric Antigen Receptor T-Cell Therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chimeric Antigen Receptor T-Cell Therapy – Analytical Perspective
  7. In-depth Commercial Assessment
  8. Chimeric Antigen Receptor T-Cell Therapy Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. JWCAR029: JW Therapeutics
  11. Mid Stage Products (Phase II)
  12. Descartes-11: Cartesian Therapeutics
  13. Early Stage Products (Phase I/II)
  14. CNCT19: CASI Pharmaceuticals/Juventas Cell Therapy
  15. Preclinical Stage Products
  16. TMUN ONC 003: Tmunity Therapeutics
  17. Inactive Products
  18. Chimeric Antigen Receptor T-Cell Therapy Key Companies 
  19. Chimeric Antigen Receptor T-Cell Therapy Key Products 
  20. Chimeric Antigen Receptor T-Cell Therapy- Unmet Needs
  21. Chimeric Antigen Receptor T-Cell Therapy- Market Drivers and Barriers 
  22. Chimeric Antigen Receptor T-Cell Therapy- Future Perspectives and Conclusion 
  23. Chimeric Antigen Receptor T-Cell Therapy Analyst Views 
  24. Chimeric Antigen Receptor T-Cell Therapy Key Companies 
  25. Appendix

 

Got Queries? Find out the related information on Chimeric Antigen Receptor T-Cell Therapy Mergers and acquisitions, Chimeric Antigen Receptor T-Cell Therapy Licensing Activities @ Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services